🔥Telegram İfşa

Sigyn Therapy is designed to address a broad spectrum of inflammatory targets, including #sepsis, by removing #cytokines and pathogenic markers from the bloodstream. $SIGY Learn more about #SigynTherapy’s potential range: sigyntherapeutics.com/therapeutic-op…

The outbreak of #COVID19 has shifted perspectives regarding therapeutic developments; it is time to consider whether broad-spectrum responses are timelier than overly complicated targeted therapies. Read more from $SIGY CEO Jim Joyce in Medical Device News Magazine: infomeddnews.com/james-joyce-si…

Sepsis continues to be a severe issue for ill patients; our goal is to address this condition and increase positive outcomes for those affected by #sepsis. #SIGY Learn more about #SigynTherapy: sigyntherapeutics.com/sigyn-therapy

Cytokine Storm Syndrome underlies many deadly diseases that currently do not have significant therapeutic options. Through our work with #SigynTherapy and #bloodpurification tech, we hope to bring a new lifesaving option to patients. $SIGY Learn more: sigyntherapeutics.com/therapeutic-op…

It’s #RareDiseaseDay! Through our ongoing clinical development, we hope to address a broad-spectrum of issues, including rare conditions like #Hepatic Encephalopathy (#HE). Learn more about supporting patients with rare conditions: rarediseaseday.org

As we progress further into 2022, we are excited to continue sharing updates on #SigynTherapy as it progresses through clinical development. #StayTuned! $SIGY In the meantime, read more about our work: sigyntherapeutics.com/about

#ICYMI: In a recent article from @Biospace, our CEO Jim Joyce covered how #blood detoxification technology like #SigynTherapy can fight antibiotic-resistant microorganisms known as #superbugs. $SIGY Read more: biospace.com/article/a-perf…

Improving #patientsafety starts with pursuing better patient outcomes. Learn more about #PatientSafetyAwarenessWeek from @ASHRM: ashrm.org/resources/pati…

In a recent ep. of @Finding_genius, our CEO Jim Joyce explains the potential benefits of a broad-spectrum blood purification device to treat life-threatening conditions. $SIGY #TuneIn here: findinggeniuspodcast.com/podcasts/thera…

Interested in learning more about our work and upcoming presentations and events? Check out the #NewsAndEvents section of our website for the latest and greatest! sigyntherapeutics.com/investors/news…

Our mission is to develop novel technologies that use blood purification to save patients’ lives. We're working to the bridge the gap of current therapeutic options through our broad-spectrum technology, #Sigyn Therapy. Learn more: sigyntherapeutics.com/about

What is #SigynTherapy? We are developing Sigyn Therapy as a broad-spectrum solution to life-threatening inflammatory conditions with limited treatment options. $SIGY Learn more: sigyntherapeutics.com/sigyn-therapy

In his CEO Notes, our CEO Jim Joyce provides comprehensive information regarding the development of our lead asset, Sigyn Therapy, which has broad-spectrum potential to help treat inflammatory conditions. $SIGY Learn more from our suite of #CEONotes: sigyntherapeutics.com/ceo-notes

We welcome Ajay Verma, M.D., Ph.D. to our Scientific Advisory Board. He's a recognized thought leader in the field of neurology and drug development, and brings decades of pharmaceutical industry experience to our team. $SIGY Learn more: bit.ly/3jHFEe1

Did you know that #cytokinestorm is a life-threatening condition involving elevated levels of circulating cytokines that can be triggered by various therapies, infections, cancers and autoimmune conditions? At #Sigyn we are creating novel therapeutic modalities for this condition

Please join us in welcoming H. David Humes, M.D., to our Scientific Advisory Board. Dr. Humes is a world-renowned scholar in the areas of nephrology, acute renal failure, biomaterials, medical devices, and extracorporeal therapy. $SIGY bit.ly/38EbhD6

We're thrilled to announce Alexander S. Yevzlin, M.D., FASN has joined our Scientific Advisory Board. He's a recognized leader in the field of Interventional Nephrology & has been involved in the development of multiple medical devices. $SIGY Learn more: bit.ly/3E9MT82

Did you know that regional disparities in sepsis incidence and mortality exist? 85% of sepsis cases and deaths worldwide occur in low- and middle-income countries. We believe that #sigyn extracorporeal system will increase access to innovative therapies around the world.

In case you missed it! Jeremy Ferrell, CPA, MBA was recently appointed as Chief Financial Officer of #Sigyn Therapeutics. He brings over 25 years of finance and operations leadership experience to our company. Learn more: bit.ly/3jBuHuB

Health care-associated infections are one of the most frequent adverse events in care delivery settings. These infections are often resistant to antibiotics and can rapidly lead to #sepsis. Novel therapies are needed, and #Sigyn Therapeutics has a new approach to treat sepsis.